Enumerating antigen-specific t-cell responses in peripheral blood: A comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis

Journal of Immunotherapy

Volumn 28, Issue 1, 2005, Pages 63-72

  Hobeika, Amy C ^a   Morse, Michael A ^a   Osada, Takuya ^a   Ghanayem, Manar ^a   Niedzwiecki, Donna ^a   Barrier, Robert ^a   Lyerly, H Kim ^a   Clay, Timothy M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CMV; ELISpot; Peptide MHC tetramer; Protective immunity; T cell

Indexed keywords

CYTOKINE; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE ANTIGEN;

ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 11344288398     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200501000-00008     Document Type: Article

References (16)

1. Morse MA, Clay TM, Hobeika AC, et al. Monitoring cellular immune responses to cancer immunotherapy. Curr Opin Mol Ther. 2001;3: 45-52.
2. Clay TM, Hobeika AC, Mosca PJ, et al. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res. 2001;7:1127-1135.
3. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
4. Czerkinsky C, Moldoveanu Z, Mestecky J, et al. A novel two colour ELISpot assay. I. Simultaneous detection of distinct types of antibody-secreting cells. J Immunol Methods. 1988;115:31-37.
5. Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods. 1998;212:89-98.
6. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002;25:97-138.
7. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 2002;8:1021-1032.
8. van der Burg SH, Menon AG, Redeker A, et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53. Clin Cancer Res. 2002;8:1019-1027.
9. Pullarkat V, Lee PP, Scotland R, et al. A phase I trial of SD-9427 (Progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res. 2003;9:1301-1312.
10. McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegaloviras matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol. 1994;43:103-110.
11. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 1996;70:7569-7579.
12. Forbes BA. Acquisition of cytomegalovirus infection: an update. Clin Microbiol Rev. 1989;2:204-216.
13. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
14. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
15. Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999;163:6292-6300.
16. Lacey SF, Villacres MC, La Rosa C, et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 HLA-B*07 alleles. Hum Immunol. 2003;64:440-452.